drug
Samsca
Marketedupdated 6mo agoby Otsuka America Pharmaceutical Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying Samsca
- phase3A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- phase3A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- —Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
- phase1A Study of HRS-9057 in Patients With Heart Failure and Volume Overload
- phase1Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Male
- phase1Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial Protocol
- —Samsca PMS in ADPKD Patients
- phase2A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia
News(2)
- Biogen-backed Estuary nabs $93M for kidney disease gene therapyThe Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."biopharma_dive · 1mo ago
- Estuary flows out of stealth with $103M to propel kidney disease gene therapies into clinicEstuary Biotherapeutics has swum out of stealth with $103 million in funding to power a pair of gene therapies into clinical trials for an inherited kidney disorder.fiercebiotech · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that